DK3820874T3 - Selektive estrogenreceptornedbrydere - Google Patents

Selektive estrogenreceptornedbrydere Download PDF

Info

Publication number
DK3820874T3
DK3820874T3 DK19746252.6T DK19746252T DK3820874T3 DK 3820874 T3 DK3820874 T3 DK 3820874T3 DK 19746252 T DK19746252 T DK 19746252T DK 3820874 T3 DK3820874 T3 DK 3820874T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
estrogen receptor
selective estrogen
selective
antagonists
Prior art date
Application number
DK19746252.6T
Other languages
English (en)
Inventor
Jeffrey Daniel Cohen
Daniel Jon Sall
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67480324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3820874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3820874T3 publication Critical patent/DK3820874T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DK19746252.6T 2018-07-12 2019-07-11 Selektive estrogenreceptornedbrydere DK3820874T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
US201962825172P 2019-03-28 2019-03-28
PCT/US2019/041342 WO2020014440A1 (en) 2018-07-12 2019-07-11 Selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
DK3820874T3 true DK3820874T3 (da) 2022-12-12

Family

ID=67480324

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19746252.6T DK3820874T3 (da) 2018-07-12 2019-07-11 Selektive estrogenreceptornedbrydere

Country Status (33)

Country Link
US (1) US12128040B2 (da)
EP (1) EP3820874B1 (da)
JP (1) JP7085056B2 (da)
KR (1) KR102577142B1 (da)
CN (1) CN112424205B (da)
AU (1) AU2019299952B2 (da)
BR (1) BR112020025381A2 (da)
CA (1) CA3105491C (da)
CL (1) CL2021000046A1 (da)
CO (1) CO2021000041A2 (da)
CR (1) CR20210006A (da)
DK (1) DK3820874T3 (da)
EC (1) ECSP21001786A (da)
ES (1) ES2932867T3 (da)
FI (1) FI3820874T3 (da)
HR (1) HRP20230080T1 (da)
HU (1) HUE061032T2 (da)
IL (1) IL279990B2 (da)
JO (1) JOP20210004B1 (da)
LT (1) LT3820874T (da)
MD (1) MD3820874T2 (da)
MX (1) MX2021000377A (da)
MY (1) MY210254A (da)
PE (1) PE20211245A1 (da)
PH (1) PH12021550048A1 (da)
PL (1) PL3820874T3 (da)
PT (1) PT3820874T (da)
RS (1) RS63876B1 (da)
SA (1) SA521421006B1 (da)
SG (1) SG11202100145YA (da)
SI (1) SI3820874T1 (da)
UA (1) UA125890C2 (da)
WO (1) WO2020014440A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102710603B1 (ko) 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
US12414945B2 (en) 2015-12-17 2025-09-16 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
BR112021000395A2 (pt) 2018-07-11 2021-04-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compostos imunomoduladores diméricos contra mecanismos baseados em cereblon
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
MX2022000279A (es) 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
TW202328099A (zh) * 2021-08-31 2023-07-16 日商衛材R&D企管股份有限公司 單環吡啶衍生物之製造方法
EP4472982A1 (en) * 2022-02-01 2024-12-11 Eli Lilly and Company Processes for the preparation of selective estrogen receptor degraders
CN119744261A (zh) 2022-08-25 2025-04-01 赛诺菲 新颖的经取代的喹啉和四氢化萘甲酸衍生物及其治疗用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
CA2218756A1 (en) * 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
ATE321754T1 (de) 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
US7329654B2 (en) 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
EP1497277A1 (en) 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
DE20301728U1 (de) * 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
EP1709021B1 (en) 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
CA2578164A1 (en) * 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
EP3303326B1 (en) * 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
US9969732B2 (en) * 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
EP3565558B1 (en) * 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
PH12021550048A1 (en) 2021-09-20
KR102577142B1 (ko) 2023-09-12
HUE061032T2 (hu) 2023-05-28
IL279990B2 (en) 2023-07-01
MD3820874T2 (ro) 2023-05-31
EP3820874B1 (en) 2022-11-30
JP7085056B2 (ja) 2022-06-15
CA3105491C (en) 2023-09-05
IL279990A (en) 2021-03-01
JOP20210004B1 (ar) 2024-04-18
CN112424205B (zh) 2023-10-31
PT3820874T (pt) 2023-01-06
UA125890C2 (uk) 2022-06-29
PE20211245A1 (es) 2021-07-13
HRP20230080T1 (hr) 2023-03-17
EP3820874A1 (en) 2021-05-19
LT3820874T (lt) 2023-02-10
AU2019299952A1 (en) 2021-01-21
CO2021000041A2 (es) 2021-01-18
ECSP21001786A (es) 2021-02-26
JP2021530486A (ja) 2021-11-11
SI3820874T1 (sl) 2023-02-28
RS63876B1 (sr) 2023-02-28
CA3105491A1 (en) 2020-01-16
CN112424205A (zh) 2021-02-26
JOP20210004A1 (ar) 2021-01-10
SG11202100145YA (en) 2021-02-25
MY210254A (en) 2025-09-04
US20210260052A1 (en) 2021-08-26
SA521421006B1 (ar) 2023-02-08
ES2932867T3 (es) 2023-01-27
FI3820874T3 (fi) 2023-03-06
BR112020025381A2 (pt) 2021-03-09
AU2019299952B2 (en) 2022-06-16
KR20210018460A (ko) 2021-02-17
CR20210006A (es) 2021-02-05
US12128040B2 (en) 2024-10-29
WO2020014440A1 (en) 2020-01-16
MX2021000377A (es) 2021-03-25
IL279990B1 (en) 2023-03-01
NZ771719A (en) 2024-02-23
CL2021000046A1 (es) 2021-06-25
PL3820874T3 (pl) 2023-02-06

Similar Documents

Publication Publication Date Title
DK3820873T3 (da) Selektive østrogenreceptornedbrydere
DK3820874T3 (da) Selektive estrogenreceptornedbrydere
EP4069686C0 (en) GLP-1 RECEPTOR AGONIST
LT3762380T (lt) Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai
IL271435A (en) T cell receptors
EP3814381A4 (en) TRISPECIFIC ANTAGONISTS
EP3442971C0 (en) ESTROGEN RECEPTOR MODULATORS
EP3386500A4 (en) Benzothiophene-based selective estrogen receptor downregulators
LT3713928T (lt) Nauji bradikinino b2 receptoriaus antagonistai
EP3630763A4 (en) CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP3806903A4 (en) CD79A CHIMERIC ANTIGEN RECEPTORS
EP3732163A4 (en) MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP3628005A4 (en) Corticotropin releasing factor receptor antagonists
EP3846806A4 (en) Muscarinic acetylcholine m1 receptor antagonists
EP3724220A4 (en) DARIC NKG2D RECEIVERS
HUE047761T2 (hu) Ösztrogén receptor modulátorok
PL3613739T3 (pl) Antagoniści integryn
DK3334721T3 (da) Cgrp-receptorantagonister
EP3609868A4 (en) TETRAHYDROQUINOLEIN DERIVATIVES USED AS P2X7 RECEPTOR ANTAGONISTS
EP4452969A4 (en) INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS
EP3902545C0 (en) NEW SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENT SALTS
EP3750879A4 (en) PROSTACYCLINE RECEPTOR AGONIST
DK3611373T3 (da) Lynreceptorbeslag
EP3849567A4 (en) ESTROGEN RECEPTOR TARGETED ANTAGONISTS
EP3889133A4 (en) ESTROGEN RECEPTOR ANTAGONIST